4th Annual G-FINDER Survey Released

Click here for full report.

Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010.

While the report shows that funding for TB R&D increased by $30M from 2009 – 2010, annual funding is still barely 25% of the figure suggested by the Stop TB Partnership as adequate to sustain the pace of R&D to bring critically-needed new TB products to the field without delay. Investments by public and philanthropic donors over the past 10 years have built a pipeline of products that will transform TB control. Turning away from these projects means that we will continue to wage the fight against TB with inadequate tools. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients–donors must commit to taking them across the finish line.

Read full report.

Read report highlights.

For those who use Twitter, here are some prepared tweets to highlight the urgent need to maintain funding for TB R&D. To use them:

  1. Sign into twitter
  2. Click any of the links below, which will automatically load
  3. Press “tweet”

Tweet #1

#PDP funding decreased for a 2nd straight year, putting 100+ global health projects in jeopardy. #RnD4NTDs #GFINDER

Click here to automatically load.

Tweet #2

A decade of work built a robust pipeline of new TB drugs. We must see them across the finish line. #RnD4NTDs #GFINDER

Click here to automatically load.

Tweet #3

#TB doesn’t heed a global financial crisis. Global health funding cuts only embolden pandemics. #RnD4NTDs #GFINDER

Click here to automatically load.

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...